Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
IncobotulinumtoxinA (100 Units)
DRUG
2 trials
Sponsors
Merz Pharmaceuticals GmbH
, Northwestern University
Conditions
Chronic Troublesome Sialorrhea
Erectile Dysfunction
Parkinson's Disease
Post-stroke
Traumatic Brain Injury
Phase 2
Efficacy of Intracavernosal Xeomin With Tadalafil for Mild-Moderate Erectile Dysfunction
Not yet recruiting
NCT07537855
Northwestern University
Erectile Dysfunction
Start: 2026-06-01
End: 2028-06-01
Target: 30
Updated: 2026-05-11
Phase 3
Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions
Completed
NCT02091739
Merz Pharmaceuticals GmbH
Chronic Troublesome Sialorrhea, Parkinson's Disease, Post-stroke +1
Start: 2014-04-30
End: 2016-11-30
Updated: 2018-03-27
Related Papers
Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks.
2019-11-26
26 citations
Long-term Efficacy and Safety of IncobotulinumtoxinA Treatment for Sialorrhea (S4.007)
Neurology
2019-04-09
1 citations
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.
2019-03-27
67 citations